Internal Medicine, Cardiovascular Disease · Montrose, CA
NPI
1801011085
Since 2007
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
2525 Honolulu Ave
Montrose, CA, 91020
Phone (818) 484-8878
Groups this clinician bills Medicare through
Medicare paid, 2024
$875K
13,775 services
Medicare patients, 2024
1,420
Average age 76
Drug cost, 2024
$2.4M
23,652 prescriptions
Company payments, 2025
$24.38
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Arsen Hovanesyan was code 99233 (hospital e&m - subsequent), 2,254 times for 402 patients. In total Arsen Hovanesyan billed 13,775 services in 51 codes, and Medicare paid $875K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 2,254 | 402 | $88.12 | $199K |
| J0153 Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | Office | 2,088 | 36 | $0.47 | $984 |
| 99213 Office E&M - Established | Office | 2,060 | 831 | $62.62 | $129K |
| 99232 Hospital E&M - Subsequent | Facility | 1,054 | 127 | $58.49 | $62K |
| 99214 Office E&M - Established | Office | 797 | 519 | $88.89 | $71K |
| 93000 Electrocardiogram | Office | 749 | 465 | $9.75 | $7,302 |
| J2785 Injection, regadenoson, 0.1 mg | Office | 636 | 158 | $3.67 | $2,335 |
| 93306 Echocardiography (TTE/TEE) | Office | 577 | 538 | $146.98 | $85K |
| 99223 Hospital E&M - Initial | Facility | 541 | 411 | $126.94 | $69K |
| 93015 Electrocardiogram | Office | 504 | 389 | $51.38 | $26K |
| A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 448 | 220 | $76.22 | $34K |
| 93306 Echocardiography (TTE/TEE) | Facility | 318 | 285 | $50.82 | $16K |
| 78452 Myocardial Perfusion Scan | Office | 224 | 220 | $354.35 | $79K |
| 99204 Office E&M - New | Office | 201 | 201 | $100.86 | $20K |
| 93010 Electrocardiogram | Facility | 185 | 179 | $6.06 | $1,122 |
By year: 2022 $1.0M for 20,773 services; 2023 $1.0M for 20,202 services; 2024 $875K for 13,775 services.
Medicare prescription drug claims, 2024
In 2024, the drug Arsen Hovanesyan prescribed most often to Medicare patients was Carvedilol, with 1,913 prescriptions and refills. In total Arsen Hovanesyan wrote 23,652 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carvedilol Generic | 1,913 | 2,295 | 256 | $6,590 |
| Metoprolol Succinate Generic | 1,406 | 1,827 | 225 | $14K |
| Furosemide Generic | 1,168 | 1,355 | 174 | $2,377 |
| Bisoprolol Fumarate Generic | 1,001 | 1,202 | 169 | $18K |
| Eliquis Apixaban | 953 | 1,085 | 147 | $641K |
| Amlodipine Besylate Generic | 948 | 1,336 | 169 | $2,043 |
| Clopidogrel Clopidogrel Bisulfate | 945 | 1,262 | 158 | $4,006 |
| Atorvastatin Calcium Generic | 835 | 1,287 | 164 | $4,599 |
| Nitroglycerin Generic | 747 | 789 | 132 | $5,870 |
| Clonidine Hcl Generic | 725 | 777 | 110 | $1,129 |
| Olmesartan Medoxomil Generic | 688 | 931 | 106 | $6,492 |
| Jardiance Empagliflozin | 650 | 751 | 96 | $439K |
| Losartan Potassium Generic | 590 | 800 | 91 | $2,373 |
| Amiodarone Hcl Generic | 492 | 616 | 84 | $5,534 |
| Rosuvastatin Calcium Generic | 490 | 662 | 85 | $3,484 |
Brand drugs: 2,984 claims; generic drugs: 20,621 claims; opioid claims: 86.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Arsen Hovanesyan $24.38 ($24.38 in general payments such as food, travel and fees) from 1 company. The largest payer was ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) with $24.38.
| Company | Payments | Amount |
|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $24.38 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.